| Business

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Mylan said to raise Meda takeover offer to $6.7B

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Staff and Wire Reports
Friday, April 25, 2014, 2:39 p.m.

Mylan Inc., the biggest domestic maker of generic medicines, raised its offer for Swedish drugmaker Meda AB to about $6.7 billion, people with knowledge of the matter said.

The all-stock offer was sent this week, said the people, who asked not to be identified discussing confidential information.

A previous Mylan bid was rejected by Meda, the Swedish company said on April 4, without saying why or disclosing the offer's amount.

Meda would help Cecil-based Mylan expand in generic and branded respiratory and dermatology drugs, and strengthen its position in emerging markets and Europe.

Among Meda's products is the allergy drug Dymista. A majority of Mylan's products are generic versions of branded pharmaceuticals. But it makes EpiPen, a branded drug used to treat severe allergic reactions.

Generic drug manufacturers have been consolidating and buying up new assets as a way to broaden their revenue to include more profitable brand-name drugs and injectable medicines that face less competition.

Mylan has said it is looking to make a “substantial” acquisition this year. The company in December completed a $1.75 billion acquisition of Agila, an Indian maker of injectable medications that doubled the size of Mylan's injectables business.

Nina Devlin, a spokeswoman for Mylan, and Paula Treutiger, a Meda spokeswoman, declined to comment.

Meda's shares were halted in Stockholm trading on Friday. Mylan gained more than 3 percent to close at $52.10.

Actavis Plc, an Irish drugmaker with operations in New Jersey, in February agreed to buy Forest Laboratories Inc. for $25 billion. Valeant Pharmaceuticals International Inc. has been gobbling up drug and health products companies as it seeks to grow into one of the world's five biggest drug manufacturers.

Valeant this week teamed with Bill Ackman, a billionaire hedge fund manager, in a $45.7 billion bid to buy Allergan Inc., the maker of the Botox cosmetic treatment.

Bloomberg News and Trib Total Media staff writer Alex Nixon contributed to this report. Nixon can be reached at 412-320-7928 or

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Business Headlines

  1. Rally in energy shares fails to lift market as biotech freefall continues
  2. Eat’n Park sells Cura division that serves hospitals and senior living
  3. Consol raises $101 million in coal asset sales
  4. ZeroFossil Energy Outfitters powers up with renewable sources
  5. PNC fined for paperwork errors on municipal bond offerings
  6. Power plants challenged by carbon capture and storage
  7. Energy efficiency goes mainstream with help of regulations, demand
  8. Alcoa lands $1B airplane fastener contract from Airbus
  9. Credit bureau Experian keeps info on cellular firm’s customers
  10. Market rises on bet that Federal Reserve won’t raise interest rates soon
  11. Koppers CEO believes struggling company can do better, transform